Dalvance: First QIDP Antibiotic Breaks New Regulatory Ground; Label Doesn’t
Executive Summary
Durata has post-marketing requirements to continue resistance-related studies, but its label includes stewardship language similar to other antibiotics.
You may also be interested in...
Dalvance Protocol Accord With FDA + Actavis Marketing = Home Run?
With a Special Protocol Agreement and an experienced sales team lined up, all the firm has to do now is get hospitals excited about an expensive antibiotic in a highly-genericized market.
Cubist’s Sivextro To Beat Durata’s Dalvance To Antibiotic Market
Second QIDP antibiotic is first to market; Cubist will stress shorter term dosing over available therapies and thinks it can rely on efficient marketing strategy for commercial success.
FDA Adds Three “Qualifying Pathogens” For Potential Antibiotic Incentives
Final rule includes a total of 21 pathogens, but agency notes a drug intended to treat a pathogen on the list is not guaranteed a QIDP designation for priority review and potential added marketing exclusivity.